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Introduction: Placenta accreta spectrum (PAS) carries a high burden of adverse 
maternal outcomes, especially significant blood loss, which can be life- threatening. 
Different management strategies have been proposed but the association of clini-
cal risk factors and surgical management options during cesarean delivery with high 
blood loss is not clear.
Material and methods: In this international multicenter study, 338 women with PAS un-
dergoing cesarean delivery were included. Fourteen European and one non- European 
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1  |  INTRODUC TION
Although maternal mortality rates are declining, the increasing inci-
dence of cesarean delivery (CD) has resulted in an increase in placenta 
accreta spectrum (PAS), or abnormally invasive placenta, adversely 
impacting maternal outcomes globally.1,2 PAS describes the clinical 
disease spectrum in which a placenta does not separate spontane-
ously at delivery and cannot be removed without causing abnormal 
and potentially life- threatening bleeding due to varying degrees of 
placental invasion into or through the myometrium.3,4 Although still 
relatively rare, PAS carries a disproportionate risk of severe maternal 
morbidity and mortality, and contributes considerably to the propor-
tion of postpartum hemorrhage with hysterectomy.5 Not only is PAS 
a heterogeneous disease spectrum, but management of pregnancies 
with PAS varies widely across centers. Management strategies in-
clude delivery by planned cesarean hysterectomy, focal myometrial 
resection and conservative management leaving the placenta in situ 
after delivery, with or without adjunctive measures such as arterial 
embolization or planned delayed hysterectomy.6
Various efforts have been made to identify associations be-
tween clinical management and maternal blood loss, morbidity and 
mortality in PAS. Most studies are conducted by single centers, with 
limited data and generalizability to guide the optimal management 
of this condition. In an attempt to address these problems, interna-
tional groups, including the International Society for PAS (IS- PAS) and 
the International Federation of Gynaecology and Obstetrics (FIGO), 
have published proposals for standardization of imaging7,8 IS- PAS has 
joined together specifically to pool international multi- center data to 
identify outcomes across various centers and identify research gaps.
We aimed to determine which epidemiologic factors and which 
management factors were associated with high and extraordinarily 
high peripartum blood loss in CD complicated by PAS.
center (USA) provided cases treated retrospectively between 2008 and 2014 and 
prospectively from 2014 to 2019. Peripartum blood loss was estimated visually and/or 
by weighing and measuring of volume. Participants were grouped based on blood loss 
above or below the 75th percentile (>3500 ml) and the 90th percentile (>5500 ml).
Results: Placenta percreta was found in 58% of cases. Median blood loss was 2000 ml 
(range: 150- 20 000 ml). Unplanned hysterectomy was associated with an increased 
risk of blood loss >3500 ml when compared with planned hysterectomy (adjusted OR 
[aOR] 3.7 [1.5- 9.4], p = 0.01). Focal resection was associated with blood loss compa-
rable to that of planned hysterectomy (crude OR 0.7 [0.2– 2.1], p = 0.49). Blood loss 
>3500 ml was less common in patients undergoing successful conservative manage-
ment (placenta left in situ, aOR 0.1 [0.0– 0.6], p = 0.02) but was more common in 
patients who required delayed hysterectomy (aOR 6.5 [1.7– 24.4], p = 0.001). Arterial 
occlusion methods (uterine or iliac artery ligation, embolization or intravascular bal-
loons), application of uterotonic medication or tranexamic acid showed no significant 
effect on blood loss >3500 ml. Patients delivered by surgeons without experience in 
PAS were more likely to experience blood loss >3500 ml (aOR 3.0 [1.4– 6.4], p = 0.01).
Conclusions: In pregnant women with PAS, the likelihood of blood loss >3500 ml was 
reduced in planned vs unplanned cesarean delivery, and when the surgery was per-
formed by a specialist experienced in the management of PAS. This reinforces the ne-
cessity of delivery by an expert team. Conservative management was also associated 
with less blood loss, but only if successful. Therefore, careful patient selection is of 
great importance. Our study showed no consistent benefit of other adjunct measures 
such as arterial occlusion techniques, uterotonics or tranexamic acid.
K E Y W O R D S
abnormally invasive placenta, cesarean, high- risk pregnancy, hysterectomy, placenta, 
postpartum hemorrhage, uterine scar
Key message
Planned procedures, including hysterectomy and focal 
resection for placenta accreta spectrum (PAS), are associ-
ated with lower blood loss than unplanned hysterectomies. 
Peripartum blood loss is less when cesarean delivery is 
managed by a surgeon or surgical team specialized in PAS.
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2  |  MATERIAL AND METHODS
2.1  |  Patient recruitment
The IS- PAS database contains both retrospectively and prospec-
tively collected obstetric and surgical data of pregnant patients >14 
gestational weeks with suspected and/or pathologically proven PAS. 
Cases from April 2008 to December 2013 were registered retro-
spectively in the database. Cases from 2014 to 2019 were collected 
prospectively. In total, 442 cases were included in the database.9
2.2  |  Exclusion criteria
Of the 442 cases in the IS- PAS database, 32 cases of women with 
normal placentation (antenatally suspected PAS with normal pla-
cental separation, ie “false positive cases”) were excluded from this 
analysis. A further 26 cases not delivered by CD (vaginal delivery 
[n = 17] and termination of pregnancy [n = 9]) were excluded. Thirty- 
one cases were excluded due to missing information on operative 
management and 15 cases due to missing data on blood loss. In total, 
338 cases were included and analyzed (Figure 1, Table S1).
2.3  |  Measurement of blood loss and clinical 
classification of PAS
Each center recorded blood loss using their own standardized local 
protocol, whether by quantified measurement or visual estimation. 
The degree of invasion was classified based on the IS- PAS Grading 
system7 originally proposed in 2015 and upon which the more 
recently published FIGO Clinical Classification system was based.8,10 
The publication by Braun et al includes further details.9
2.4  |  Data collection
Data were collected both retrospectively (cases managed from 
2008 to 2014) and prospectively (2014– 2019) via chart review using 
a standardized, secured and password- protected online data col-
lection platform (FetView, Zeitgeist Health SE).9 Participants were 
grouped based on blood loss in this study above the 75th percentile 
of our cohort (>3500 ml) and blood loss above the 90th percentile 
(>5500 ml) (Appendix S1).
The following factors were investigated with regard to their as-
sociation with peripartum blood loss:
• Number of previous CD
• Presence of placenta previa
• Antenatal PAS diagnosis (antenatally suspected vs unsuspected 
PAS)
• IS- PAS grades of invasion 2– 68
• Degree of urgency of delivery
• Experience of the surgeon: specialist in PAS vs gynecologist/ob-
stetrician with no particular training in PAS (definition: an expert 
is a person with significant experience in PAS and a high level of 
knowledge and/or skills relating to the condition)11
• Operative management
– Type of management (planned hysterectomy, unplanned hys-
terectomy, focal resection, placenta left in situ with uncom-
plicated resorption, placenta in situ followed by planned or 
unplanned delayed hysterectomy)
– Position of the uterine incision (fundal, lower transverse, 
transverse above placenta)
• Measures to support uterine contraction/aid blood clotting
– Oxytocin (prophylactic administration – before increased 
blood loss occurred; therapeutic administration – after in-
creased blood loss occurred)
– Tranexamic acid (TXA; prophylactic administration – before 
increased blood loss occurred; therapeutic administration – 
after increased blood loss occurred)
– Prostaglandin F2α/E2/E1 (prophylactic administration – be-
fore increased blood loss occurred; therapeutic administration 
– after increased blood loss occurred)
– Intrauterine balloon (prophylactic administration – before 
increased blood loss occurred; therapeutic administration – 
after increased blood loss occurred)
• Perioperative occlusion of uterine blood supply (no other types of 
occlusion reported):
– Pelvic arterial embolization
– Intravascular balloon (femoral or iliac)
– Uterine artery ligation
– Internal iliac artery ligation
F I G U R E  1  Selection of cases. CD, cesarean delivery; PAS, 
placenta accreta spectrum
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2.5  |  Statistical analyses
Univariate and multivariate analyses were used to test associations 
with blood loss >3500 and >5500 ml. A multilevel logistic regression 
model served to control for possible variation between participat-
ing centers (Appendix S1). The 15 centers were defined as a sec-
ond level variable. As a first step, the influence on peripartum blood 
loss was calculated for each first level variable separately (univariate 
analysis). In analyses comparing planned management approaches, 
planned hysterectomy was the reference category for operative 
management, as this is the most commonly used, definitive imme-
diate treatment of placenta accreta spectrum.12 Crude odds ratios 
(cOR) with 95% confidence interval (95% CI) were calculated for all 
results. Next, a multivariate regression analysis was carried out, in-
cluding variables that had been identified as having a significant ef-
fect in univariate analysis (p ≤ 0.05). Multivariate analyses yielded 
adjusted odds ratios (aOR) with 95% CI.
2.6  |  Ethical approval
Local Ethical Committee/IRB approval and Data Use Agreements 
were obtained according to local policies. Details of these can be 
found in the online Supporting Information contained in the second 
Commentary of this supplement.9
3  |  RESULTS
3.1  |  Demographic, clinical and outcome 
characteristics of enrolled women
Table 1 shows the demographic data of the analyzed cases. Placenta 
percreta (PAS grade 4– 6) was present in 58% of cases. Overall, 
median blood loss was 2000 ml (range 150– 20 000 ml, Figure 2A). 
Perioperative occlusion of uterine blood supply was used in 28% 
(95/338) of cases. Among these cases, it was used therapeutically 
in 46% (44/95) of cases, that is, after occurrence of high blood loss. 
The most commonly used prophylactic intervention was intravas-
cular balloon placement (48/338; 14%). Overall, a reduction in total 
blood loss was seen over time (Figure 2B).
3.2  |  Factors not significantly associated with high 
peripartum blood loss
Tables 2 and 3 show the results of the multilevel logistic regression 
analyses. Blood loss >3500 ml or >5500 ml did not differ between 
centers (inter- center variance 1.3 [0.3– 4.9], p = 0.15). The number 
of previous CD, the presence of placenta previa and antenatal diag-
nosis of PAS showed no association with perioperative blood loss. 
No difference in blood loss was noted between focal resection and 
planned hysterectomy. Focal resection was performed in 26 cases: 
three times in PAS grade 2, two times in PAS grade 3, 18 times in 
PAS grade 4, one time in PAS grade 5, two times in PAS grade 6. 
Univariate analyses did not yield significant correlations between 
measures to promote uterine contraction (administration of utero-
tonics, intrauterine balloon) or blood loss >3500 ml. No difference in 
blood loss was seen with prophylactic use of TXA (univariate analy-
ses: >3500 ml: cOR 0.5 [0.2– 1.2], p = 0.12; >5500 ml: cOR 0.3 [0.1– 
1.5], p = 0.14; prophylactic TXA] n = 53, [no TXA] n = 182. Blood 
loss >5500 ml was not significantly associated with type or timing of 
surgical intervention (aOR 2.4 [0.9– 6.6], p = 0.08 for unplanned hys-
terectomy; aOR 0.9 [0.1– 6.5], p = 0.92 for delayed hysterectomy). 
Univariate analyses showed increased association between cases 
with blood loss >3500 and blood loss >5500 ml in emergent CD vs 
scheduled CD (cOR 3.5 [1.2– 10.2], p = 0.02 and cOR 2.6 [1.0– 6.8], 
p = 0.04, respectively), but not after multivariate analysis. Univariate 
analyses did not yield significant correlations between perioperative 
occlusion of uterine blood supply available in our dataset (uterine 
artery embolization, femoral balloon, uterine artery ligation, internal 
iliac artery ligation) and blood loss >3500 or >5500 ml.
3.3  |  Factors associated with significantly 
increased risk for high peripartum blood loss
Compared with planned hysterectomy, unplanned hysterectomy 
was associated with significantly higher odds of blood loss >3500 
ml (aOR 3.7 [1.5– 9.4], p = 0.01). The association with blood loss 
>5500 ml did not hold in multivariate analysis (aOR 2.4 [0.9– 6.6], 
p = 0.08). Delayed hysterectomy was associated with a significantly 
higher likelihood of total blood loss >3500 ml (aOR 6.5 [1.7– 24.4], 
p = 0.001). Placenta percreta with parametrial invasion (Grade 6) 
showed a trend to a higher proportion of cases with blood loss 
>3500 ml (aOR 3.4 [0.9– 12.3], p = 0.06), with insignificant results 
in terms of blood loss >5500 ml (aOR 1.9 [0.6– 7.0], p = 0.32). There 
was a positive correlation between therapeutic internal iliac artery 
ligation and blood loss >3500 ml (cOR 4.4 [1.2– 16.2], p = 0.03). 
Manual removal of placenta was attempted significantly less fre-
quently in the blood loss >3500 ml group and only performed in 
lower PAS grades of invasion (grades 2 and 3; aOR 0.2 [0.1– 0.6], 
p = 0.01).
3.4  |  Factors associated with significantly reduced 
risk for high peripartum blood loss
Interestingly, fewer cases with blood loss >3500 ml occurred for 
placenta percreta grade 4 in multivariate analysis (aOR 0.4 [0.1– 
0.9]; p = 0.04, reference category: PAS grade of invasion 2). This 
was more pronounced for blood loss >5500 ml (aOR 0.2 [0.1– 0.8], 
p = 0.01). Leaving the placenta in situ was associated with fewer 
cases of blood loss >3500 ml but only if it was successful without 
further interventions (aOR 0.1 [0.0– 0.6], p = 0.02). Delivery by a sur-
geon experienced in PAS was strongly related to blood loss >3500 
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TA B L E  1  Demographic, clinical and outcome characteristics of 
enrolled women (n = 338)




Maternal age, yearsa  34.6 (34.1– 35.2)
Gravidityb  3 (2– 5)
Parityb  2 (1– 3)
Number of prior cesarean deliveriesc  338 100
0 (no prior cesareans) 56 17
1 prior cesarean 135 40
≥2 prior cesareans 147 43
Placenta previac  298 88
Outcome characteristics
Gestational age at delivery in weeksb  36 (34– 37)
Cesarean deliveryc  338 100
PAS diagnosed antenatallyc  306 91
Operative managementc 
Planned cesarean hysterectomy 182 54
Unplanned cesarean hysterectomy 40 12
Focal resection 26 8
Leaving placenta in situ 24 7
Leaving placenta in situ + delayed 
HE
15 4
Manual removal of placenta 51 15
PAS Gradingc 
Grade of invasion 2 79 23
Grade of invasion 3 62 18
Grade of invasion 4 123 37
Grade of invasion 5 48 14
Grade of invasion 6 26 8
Blood loss in ml (range)b,c  2000 
(150– 20 000)
Blood loss >3500 ml 92 27
Blood loss <3500 ml 246 73
Blood loss >5500 ml 33 10
Blood loss <5500 ml 305 90
Transfused red packed cells (range)b,c  2 (0– 108)
0– 1 red packed cells 153 45
2– 4 red packed cells 86 26
More than four red packed cells 99 29
Oxytocinc  321d  95
No oxytocin (reference) 156 49
Prophylactic oxytocin 113 35
Therapeutic oxytocin 52 16
Prostaglandinc  336d  98
No prostaglandin (reference) 275 81
Prophylactic prostaglandin 13 4
Therapeutic prostaglandin 48 14
(Continues)
Variable n = 338
% of 
cases
Tranexamic acidc  330d  98
No tranexamic acid (reference) 182 54
Prophylactic tranexamic acid 53 16
Therapeutic tranexamic acid 95 28
Urgency of cesarean deliveryc  337d  100
At a time to suit the woman and 
maternity team (elective)
228 68
Needing early delivery but no 
maternal or fetal compromise
44 13
Maternal or fetal compromise 
which is not immediately 
life- threatening
50 15
Immediate threat to life of woman 
or fetus (crash)
15 5
Grade of surgeonc  325d  96
Specialist in PAS (reference) 249 77
No specialist 76 23
Position of uterine incisionc  323d  96
Lower transverse (reference) 98 30
Fundal 157 49
Transverse above placenta 68 21
Intravascular balloonc  337d  100




No embolization (reference) 319 94
Prophylactic 2 1
Therapeutic 14 4
Uterine artery ligationc  338 100
No ligation (reference) 321 95
Prophylactic 1 0
Therapeutic 16 5
Internal iliac artery ligationc  338 100
No ligation (reference) 328 97
Prophylactic 0 0
Therapeutic 10 3
Intrauterine balloonc  334d  99
No balloon (reference) 289 86
Prophylactic 9 3
Therapeutic 36 11
Maternal death 0 0
Abbreviations: PAS, placenta accreta spectrum.
aData presented as mean (95% CI). 
bData presented as median (IQR). 
cData presented as n (%). 
dCase numbers that do not add up to 338 cases (100%) denote missing 
data. 
TA B L E   1  (Continued)
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and >5500 ml (multivariate analyses: >3500 ml: aOR 3.0 [1.4– 6.4], 
p = 0.01; >5500 ml: aOR 4.0 [1.6– 9.9], p = 0.003, respectively).
4  |  DISCUSSION
As reported elsewhere, planned cesarean hysterectomy remains the 
most common treatment method used within our multi- center in-
ternational cohort.12,13 Conservative management, whether by leav-
ing the placenta in situ or via partial myometrial resection has been 
shown to be feasible, with favorable short- term maternal outcomes 
and subsequent fertility.14- 16 To date, it is unclear whether conserva-
tive approaches confer a significant reduction in peripartum blood 
loss. Within this cohort, leaving the placenta in situ was associated 
with lower odds of blood loss >3500 ml compared with planned ce-
sarean hysterectomy when successful (62% of cases, n = 24). When 
hysterectomy was performed as a delayed procedure (38% of cases, 
n = 15, including planned and unplanned), it was associated with 
higher odds of total blood loss >3500 ml or >5500 ml. Additionally, 
leaving the placenta in situ confers risks of secondary postpartum 
hemorrhage, sepsis or disseminated intravascular coagulation.15- 17 
A multicenter retrospective case series by Palacios- Jaraquemada 
et al on outcomes after resective- reconstructive techniques has 
compared the blood loss of 326 patients with different topographic 
forms of PAS.14 The median blood loss of the 338 cases in our study 
was 2000 ml (interquartile range [IQR] 1000– 3500 ml). This is simi-
lar to, but with a wider range, compared with the results of Palacios- 
Jaraquemada et al.14 Although this was not the subject of this study, 
it seems possible that specific hemostasis over pedicles that irrigate 
the placenta and the invaded area can help to reduce blood loss 
>3500 ml.
Interestingly, the odds for blood loss >3500 ml were similar be-
tween focal resection and planned hysterectomy. This suggests that 
focal resection is a feasible option for women who want to keep 
their uterus, when the location and size of placental invasion per-
mits this procedure.
There was no significant association of blood loss >3500 and 
>5500 ml and the use of adjunctive measures to reduce blood loss, 
including use of the anti- fibrinolytic medication (TXA). Therapeutic 
use of TXA positively correlated with blood loss >3500 ml (OR 2.4 
[1.4– 4.2; p = 0.001). This positive correlation likely reflects the indi-
cation of ongoing bleeding rather than a failure of efficacy. Overall, 
the prophylactic use of adjunctive measures was relatively infre-
quent within the cohort. In the TRAAP study, a large multicenter 
study from France published in 2018, no difference in the rate of 
blood loss <500 ml was seen between women receiving oxytocin 
alone or oxytocin plus prophylactic TXA.18 One recently published 
double- blinded randomized controlled study (46 patients) demon-
strated that TXA during surgery for PAS (without specification of 
the grade of invasiveness) was effective in significantly reducing the 
intraoperative blood loss compared with the placebo group.19 Well- 
designed and appropriately powered studies to address the safety 
and efficacy of adjunctive measures are essential to understand 
their utility. Newer studies suggest that arterial occlusion of the 
aorta reduces blood loss in PAS patients.20,21 In a recent randomized 
controlled trial that included 100 women with placenta previa and 
different grades of PAS, the use of intraoperative bilateral internal 
iliac artery balloon occlusion did not reduce the number of units of 
packed red blood cells transfused or otherwise improve outcomes.22
Even placenta accreta or increta (lower grades) can be associated 
with blood loss >3500 and >5500 ml. Conversely, in placenta per-
creta (higher grades), blood loss >3500 ml occurred more frequently 
in cases involving placental invasion into other organs, whereas 
placenta percreta without invasion of other organs was associated 
with lower blood loss. One reason might be that PAS Grade 4 can 
be easily detected both on antenatal ultrasound as well as intraop-
eratively, so that manual removal of the placenta was not attempted, 
yet compared with PAS infiltrating urinary bladder or other organs 
(PAS Grade 5 or 6), the surgical complexity in PAS Grade 4 is man-
ageable. Lesser degrees of invasion may permit partial placental sep-
aration and bleeding from the placental bed or greater willingness 
on the part of the provider to attempt manual placental extirpation, 
F I G U R E  2  Scatter plots showing blood loss according to PAS grade of invasion (A) and the year of delivery (B). Mean blood loss in ml 
(± 95% CI) per grade: Grade 2: 2834 (2085– 3583), Grade 3: 2808 (2289– 3327), Grade 4: 2048 (1792– 2304), Grade 5: 3311 (2342– 4279), 
Grade 6: 3508 (2230– 4785). Non- significant tendency toward lower blood loss in PAS Grade 4 (p = 0.05, Kruskal- Wallis test). PAS Grade 1 is 
not shown as it denotes normal placentation. 3500 ml (75th percentile) and 5500 ml (90th percentile) are marked to illustrate the thresholds 
used to compare cases with high peripartum blood loss
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Blood loss >3500 ml (75. P.)
Univariate analysis Multivariate analysis
Crude odds ratio 
(95% CI) p value
Adjusted odds 
ratio (95% CI) p value
Number of previous cesarean deliveries 338 1.1 (0.9– 1.3) 0.53 n/i
Placenta previa 338 1.3 (0.6– 2.9) 0.48 n/i
PAS diagnosed antenatally 338 0.7 (0.3– 1.5) 0.36 n/i
Operative management <0.001 <0.001
Planned caesarean hysterectomy (reference) 182
Unplanned caesarean hysterectomy 40 3.9 (1.8– 8.7) 0.001 3.7 (1.5– 9.4) 0.01
Focal resection 26 0.7 (0.2– 2.1) 0.49 n/s
Leaving placenta in situ 24 0.1 (0.0– 0.9) 0.04 0.1 (0.0– 0.6) 0.02
Leaving placenta in situ + delayed HE 15 4.6 (1.4– 14.6) 0.01 6.5 (1.7– 24.4) 0.001
Manual removal of placenta 51 0.4 (0.2– 0.9) 0.04 0.2 (0.1– 0.6) 0.01
PAS Grading 0.005 0.001
Grade of invasion 2 (reference) 79
Grade of invasion 3 62 1.5 (0.7– 3.2) 0.31 0.6 (0.2– 1.6) 0.28
Grade of invasion 4 123 0.6 (0.3– 1.3) 0.17 0.4 (0.1– 0.9) 0.04
Grade of invasion 5 48 1.8 (0.8– 4.1) 0.14 1.1 (0.4– 3.1) 0.91
Grade of invasion 6 26 2.7 (1.0– 7.3) 0.04 3.4 (0.9– 12.3) 0.06
Oxytocin 0.25
No oxytocin (reference) 156
Prophylactic oxytocin 113 0.8 (0.4– 1.3) 0.32 n/i
Therapeutic oxytocin 52 1.4 (0.7– 2.7) 0.34 n/i
Prostaglandin 0.16
No prostaglandin (reference) 275
Prophylactic prostaglandin 13 2.7 (0.8– 9.4) 0.11 n/i
Therapeutic prostaglandin 48 1.9 (0.9– 3.8) 0.08 n/i
Tranexamic acid 0.001
No tranexamic acid (reference) 182
Prophylactic tranexamic acid 53 0.5 (0.2– 1.2) 0.12 n/i
Therapeutic tranexamic acid 95 2.4 (1.4– 4.2) 0.001 n/i
Urgency of cesarean delivery 0.05 0.82
At a time to suit the woman and maternity team (elective, 
reference)
228
Needing early delivery but no maternal or fetal compromise 44 0.8 (0.4– 1.9) 0.64 0.8 (0.3– 2.0) 0.63
Maternal or fetal compromise which is not immediately 
life- threatening
50 1.8 (0.9– 3.9) 0.11 1.1 (0.4– 3.1) 0.78
Immediate threat to life of woman or fetus (crash) 15 3.5 (1.2– 10.2) 0.02 1.6 (0.4– 6.3) 0.48
Grade of surgeon 0.001 0.01
Specialist in PAS (reference) 249
No specialist 76 2.6 (1.5– 4.4) 0.001 3.0 (1.4– 6.4) 0.01
Position of uterine incision 0.83
Lower transverse (reference) 98 n/i
Fundal 157 1.0 (0.6– 1.8) 0.07 n/i
Transverse above placenta 68 1.2 (0.6– 2.5) 0.62 n/i
(Continues)
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whereas deep invasion is associated with bleeding risk from exten-
sive neovascularization. Our data clearly demonstrate the need for 
availability of blood products, no matter what the degree of antic-
ipated invasion. Surgical vigilance, prompt hemorrhage control and 
early correction of coagulopathy are paramount in all cases.
The data clearly show that experience matters. The presence of 
a senior surgeon with expertise in the management of PAS showed 
the strongest correlation with reduced odds of blood loss >3500 and 
>5500 ml. The risk for blood loss >3500 and >5500 ml did not vary 
among centers, even though over this study period, each center fol-
lowed local protocols, rather than a single, standardized treatment 
guideline. The importance of an experienced team is consistent with 
findings of others and underscores the importance of timely referral 
of patients to a PAS center where an experienced, multidisciplinary 
team is available.23 We observed a trend toward less maternal blood 
loss over time during the study period, suggestive of a learning curve 
among participating centers.
This study provides insight into the actual treatment rendered 
across multiple, international referral centers within the International 
Society of Placenta Accreta Spectrum (IS- PAS) over a 12- year epoch. 
As a (partly retrospective) analysis of a contemporaneously collected 
cohort, it includes the limitations inherent with such an analysis. 
All participating centers are in high- resource settings and have es-
tablished PAS treatment teams, therefore, our results may not be 
generalizable to centers in low- income countries or without multi-
disciplinary team care. There was no standardized way to measure 
or estimate peripartum blood loss, which we tried to account for, 
using multilevel regression analysis. The extent of placental invasion 
was graded using the system available grading system at the time,7,8 
which differs slightly compared with the FIGO grading system, spe-
cifically in the differentiation between placenta accreta and increta. 
As with any grading system, it is possible that different centers as-
signed these grades slightly differently between cases; however, 
we believe that the use of a standardized grading system based on 
clinical criteria at the time of delivery is far more accurate than the 
use of a system of descriptors based solely on pathologic evaluation, 
which inherently cannot take into consideration the appearance of 
tissues and structures when the placenta and uterus remain in vivo 
and excludes cases managed expectantly. Another way to classify 
placenta accreta spectrum is to categorize its topography depending 
on the blood supply.14,24 Topographic placental invasion has been 
shown to correlate with intraoperative blood loss.14 As topographic 
classifications have not been endorsed by the IS- PAS or FIGO, our 




Blood loss >3500 ml (75. P.)
Univariate analysis Multivariate analysis
Crude odds ratio 
(95% CI) p value
Adjusted odds 
ratio (95% CI) p value
Intravascular balloon 0.70
No balloon (reference) 285
Prophylactic 48 0.7 (0.3– 1.6) 0.40 n/i
Therapeutic 4 n/a 0.97 n/i
Pelvic arterial embolization 0.68
No embolization (reference) 319
Prophylactic 2 0.8 (0.2– 3.1) 0.83 n/i
Therapeutic 14 0.8 (0.1– 7.6) 0.78 n/i
Uterine artery ligation 0.25
No ligation (reference) 321
Prophylactic 1 0 (n/a) 0.94 n/i
Therapeutic 16 2.4 (0.9– 6.9) 0.10 n/i
Internal iliac artery ligation 0.03
No ligation (reference) 328
Prophylactic 0 n/a n/i
Therapeutic 10 4.4 (1.2– 16.7) 0.03 n/i
Intrauterine balloon 0.04
No balloon (reference) 289
Prophylactic 9 0.4 (0.0– 3.0) 0.35 n/i
Therapeutic 36 2.7 (1.3– 5.6) 0.01 n/i
Note: Data presented as odds ratio (95% CI). Statistically significant p values (< 0.05) are written in bold.
Abbreviations: HE, hysterectomy; n/a, not available; n/i, not included in multivariate analysis; n/s, not significant; PAS, placenta accreta spectrum.
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Blood loss >5500 ml (90. P.)
Univariate analysis Multivariate analysis
Crude odds ratio 
(95% CI) p value




Number of previous cesarean deliveries 338 0.9 (0.7– 1.3) 0.60 n/i
Placenta previa 338 1.2 (0.4– 3.9) 0.71 n/i
PAS diagnosed antenatally 338 1.3 (0.4– 4.9) 0.67 n/i
Operative management 0.049 0.01
Planned cesarean hysterectomy (reference) 182
Unplanned cesarean hysterectomy 40 2.9 (1.1– 7.5) 0.03 2.4 (0.9– 6.6) 0.08
Focal resection 26 0.6 (0.1– 3.0) 0.52 1.3 (0.3– 6.3) 0.73
Leaving placenta in situ 24 n/a 0.99 0.2 (0.0– 1.7) 0.13
Leaving placenta in situ + delayed HE 15 1.6 (0.3– 9.5) 0.62 0.9 (0.1– 6.5) 0.92
Manual removal of placenta 51 0.1 (0.0– 1.0) 0.06 0.1 (0.1– 0.6) 0.01
PAS grading 0.02 0.002
Grade of invasion 2 (reference) 79
Grade of invasion 3 62 0.8 (0.3– 2.5) 0.71 0.3 (0.1– 0.9) 0.03
Grade of invasion 4 123 0.2 (0.1– 1.8) 0.03 0.2 (0.1– 0.8) 0.01
Grade of invasion 5 48 1.0 (0.3– 3.3) 0.95 0.3 (0.1– 1.2) 0.09
Grade of invasion 6 26 2.5 (0.7– 8.4) 0.14 1.9 (0.6– 7.0) 0.32
Oxytocin 0.09
No oxytocin (reference) 156
Prophylactic oxytocin 113 0.9(0.4– 2.5) 0.91 n/i
Therapeutic oxytocin 52 2.6 (1.0– 6.8) 0.05 n/i
Prostaglandin 0.30
No prostaglandin (reference) 275
Prophylactic prostaglandin 13 2.6 (0.5– 14.2) 0.28 n/i
Therapeutic prostaglandin 48 1.3 (0.4– 3.8) 0.68 n/i
Tranexamic acid 0.45
No tranexamic acid (reference) 182
Prophylactic tranexamic acid 53 0.3 (0.1– 1.5) 0.14 n/i
Therapeutic tranexamic acid 95 1.0 (0.4– 2.4) 0.93 n/i
Urgency of cesarean delivery 0.05 0.55
At a time to suit the woman and maternity team (elective, 
reference)
228
Needing early delivery but no maternal or fetal compromise 44 0.3 (0.0– 2.1) 0.20 0.4 (0.1– 1.8) 0.23
Maternal or fetal compromise which is not immediately 
life- threatening
50 2.6 (1.0– 6.8) 0.04 1.4 (0.5– 4.1) 0.53
Immediate threat to life of woman or fetus (crash) 15 2.7 (0.7– 11.2) 0.16 0.9 (0.2– 3.8) 0.85
Grade of surgeon 0.001 0.003
Specialist in PAS (reference) 249
No specialist 76 4.3 (1.9– 10.0) 0.001 4.0 (1.6– 9.9) 0.003
Position of uterine incision 0.17
Lower transverse (reference) 98 n/i
Fundal 157 0.4 (0.1– 1.0) 0.06 n/i
Transverse above placenta 68 0.8 (0.3– 2.0) 0.56 n/i
(Continues)
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therefore such an analysis of the existing cases is not feasible. The 
analysis of perioperative arterial occlusion is limited by low case 
numbers, regional availability of such interventions; because these 
measures are frequently used in escalation and response to active 
bleeding, rather than prophylaxis, correlation with high blood loss is 
also possibly confounded by reversed causation. As the cohort in-
cluded only patients with uterine or internal iliac artery ligation, the 
impact of ligation of other pelvic arteries was not evaluated. Due to 
the partly retrospective design, our data do not allow us to conclude 
that non- significant variables have no association with blood loss, 
especially for variables that may be underpowered. Such questions 
would ideally be answered through well- designed randomized con-
trolled trials.
5  |  CONCLUSION
Even PAS with low degrees of invasion (IS- PAS Grades 2 and 3) was 
associated with high peripartum blood loss. Blood loss could not be 
accurately predicted by the anticipated degree of placental inva-
sion. No correlation of adjunctive measures or prior knowledge of 
clinical aspects such as the number of previous cesarean deliveries, 
the presence of placenta previa or antenatally diagnosed PAS with 
the incidence of high peripartum blood loss could be shown in our 
cohort. For PAS (IS- PAS Grades 2– 6), lower blood loss was equally 
observed during planned hysterectomies and planned focal resec-
tions. The incidence of high blood loss was lowest when patients 
were treated by surgeons specialized in PAS. Well- designed and ap-
propriately powered studies to address the safety and efficacy of 
adjunctive measures are essential to understand their utility.
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Blood loss >5500 ml (90. P.)
Univariate analysis Multivariate analysis
Crude odds ratio 
(95% CI) p value





No balloon (reference) 285
Prophylactic 48 6.7 (0.8– 56.0) 0.08 n/i
Therapeutic 4 0.7 (0.2– 2.4) 0.61 n/i
Pelvic arterial embolization 0.60
No embolization (reference) 319
Prophylactic 2 2.4 (0.2– 26.5) 0.48 n/i
Therapeutic 14 2.0 (0.4– 9.8) 0.41 n/i
Uterine artery ligation 0.75
No ligation (reference) 321
Prophylactic 1 n/a 0.98 n/i
Therapeutic 16 1.9 (0.4– 9.2) 0.45 n/i
Internal iliac artery ligation 0.20
No ligation (reference) 328
Prophylactic 0 n/a n/i
Therapeutic 10 3.1 (0.6– 16.9) 0.20 n/i
Intrauterine balloon 0.02
No balloon (reference) 289
Prophylactic 9 n/a 0.99 n/i
Therapeutic 36 4.1 (1.7– 10.0) 0.002 n/i
Note: Data presented as odds ratio (95% CI). Statistically significant p values (< 0.05) are written in bold.
Abbreviations: HE, hysterectomy; n/a, not available; n/i, not included in multivariate analysis; n/s, not significant; PAS, placenta accreta spectrum.
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